Max Diehn received his undergraduate degree in Biochemical Sciences from Harvard College and his M.D./Ph.D. from Stanford University in 2004. He subsequently completed radiation oncology residency at Stanford in 2009. He then joined the faculty and currently is the CRK Faculty Scholar and Associate Professor, Division Chief of Radiation and Cancer Biology, and Vice Chair of Research in the Department of Radiation Oncology.

Dr. Diehn is a physician scientist and practicing radiation oncologist who specializes in the treatment of lung cancer. His research program spans laboratory, translational, and clinical studies. The majority of his research efforts are focused on the development and application of liquid biopsy technologies for cancer screening, treatment response assessment, and detection of minimal residual disease. His group also studies mechanisms of resistance to radiotherapy, immunotherapy and targeted therapies.

Dr. Diehn has served on committees for a number of national and international organizations including IASLC, NCI, ASCO, and AACR. He is a Scientific Editor for Cancer Discovery and serves on the Thoracic Malignancies Steering Committee of the NCI. He has participated in ESMO’s Translational Research & Precision Medicine Working Group project on liquid biopsies. Dr. Diehn has been recognized with a variety of awards, including the NIH Director’s New Innovator Award, the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and election into the American Society for Clinical Investigation.

Prof. Rolfo is the Associate Director of Clinical Research at the Center for Thoracic Oncology, Tisch Cancer Institute in Mount Sinai System . In addition, he is Professor of Medicine at the Division of Hematology and Oncology at Icahn School of Medicine, Mount Sinai, New York, NY, USA.
From April 2018 to May 2021 he was serving as Director of Thoracic Medical Oncology and Director of Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), in Baltimore, Maryland, USA. In addition, he was appointed Professor of Medicine at the Division of Oncology at Maryland University, School of Medicine. Prof. Rolfo is Medical Oncologist focused in Thoracic Oncology, Drug Development and Translational Oncology.
From 2012 to March 2018 he was working as Director of the Phase I - Early Clinical Trials Unit, Director of the Clinical Trials Management Program at Antwerp University Hospital, and Senior Staff member of Thoracic Oncology Cluster at Antwerp University Hospital in Belgium. In addition he is Professor of Oncology at Antwerp University in the Center for Oncological Research (CORE) in Antwerp, Belgium,
Professor Rolfo graduated with a degree in medicine from the National University of Córdoba, Argentina in 1996; he then studied at the University of Milan and the National Cancer Institute of Milan, Italy, receiving European Oncology Board certification in 2003, followed by Spanish Board Certification in Medical Oncology in 2007. He obtained a PhD and Doctor Europaeus in Clinical and Experimental Oncology Research cum laude from the University of Palermo, Italy in 2009 under the direction of Professor Rosell, and a Master of Business Health Administration from the Polytechnic University of Valencia, Spain in 2010. He worked as clinical researcher in the Spanish Lung Cancer Group in Mallorca, Spain for 8 years.
He is actively working on drug development and Lung cancer & Mesothelioma treatment. His research is focused in molecular oncology and Immunotherapy in Thoracic Oncology and in a pan-tumoral approach, using new techniques in liquid biopsies, specifically in exosome isolation and circulating free tumour DNA. His group identify ALK translocation in exosomes in NSCLC patients, showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working in the identification of new biomarkers involved in immunotherapy and TKI drug-resistance. In Drug development Prof. Rolfo contributed to the development of several compounds including Erlotinib, pharmacokinetics of Olaparib, Entrectinib among several drugs in early phase.
Prof. Rolfo served as an expert member of the Commission for Medicinal Products for Human Use and First in Human Drugs Commission at the Federal Agency of Health and Medicinal Products from Belgium and external expert for the European Agency of Medicine (EMA).
Professor Rolfo is the Deputy Chair of the educational committee at the International Association for the Study of Lung Cancer (IASLC), served on the membership committee of ESMO, is the current vice-president of the International Society of Liquid Biopsy (ISLB) and member of the American Society of Clinical Oncology (ASCO), American Society of Clinical Research (AACR) the Oncology Latin-American Association (OLA) and other prestigious societies. He has been the recipient of numerous professional accolades, including an Honorary Doctorate by UPSJB in Peru as well Visiting Professor in Saudi Arabia, Italy and Distinguish Professor by his Alma mater University in Argentina. He has been a speaker at national and international forums in lung cancer, liquid biopsy and drug development, and has published extensively in peer-reviewed journals including New England Journal of Medicine, Lancet Oncology, Cancer Discovery, Nature Nanotechnology, Clinical Cancer Research, Annals of Oncology, and Lung Cancer among others. Prof. Rolfo is Editor in Chief of Critical Review in Oncology Hematology.

Dr. Maria Arcila is a molecular pathologist and is the director of the Diagnostic Molecular Pathology Laboratory at Memorial Sloan Kettering Cancer Center. Her practice focuses on the development and validation of technology to determine the genetic characteristics of tumors which can then be utilized as markers for disease diagnosis, treatment, risk assessment and longitudinal monitoring. She has a specific interest in the assessment of genetic markers using liquid biopsies and tumor tissues obtained through minimally invasive procedures, with an extensive publication history based on this technology. Dr. Arcila has served in multiple committees to establish guidelines of the use of molecular markers and techniques for the study of cancer including the CAP/IASLC/AMP Molecular Testing Guideline for lung cancer and the Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels.

Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and is Professor in the Department of Medicine, and Adjunct Professor in the Institute of Health Policy, Management and Evaluation at the University of Toronto. She holds the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development through the Princess Margaret Cancer Foundation. She has published over 300 peer-reviewed papers, has held (as principal or co-investigator) over $60 million in peer-reviewed grant funding, and has mentored many oncology trainees that have gone on to leadership roles in oncology around the world. In 2019, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award).

Dr Leighl’s main interest is in developing new treatments in lung cancer and improving lung cancer diagnostics. She is involved in clinical studies of novel agents for the treatment of thoracic cancers, has led several international and cooperative group studies in lung cancer and has served as a member of the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group. She was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference in Lung Cancer, and serves on multiple committees including the ASCO Thoracic Guidelines Advisory Group, ESMO Scientific and Educational Committees (Metastatic Lung Track), is co-section editor of The Oncologist and Current Oncology, an editorial board member of the Journal of Thoracic Oncology, British Journal of Cancer, a member of the IASLC Quality and Value Committee, on the Scientific Advisory Board of the Lung Cancer Foundation of America, and was recently elected to the Board of Directors of the Americas Health Foundation. Previously she served as Web Editor of the Journal of Thoracic Oncology, on the editorial board of the Journal of Clinical Oncology, the Royal College of Physicians & Surgeons of Canada Medical Oncology Examination Board, and is Past President of Lung Cancer Canada.